Esperion Gets $33M To Continue Work On Cholesterol BusterThe Ann Arbor biotech firm Esperion Therapeutics Inc. announced that it has completed a $33 million preferred stock financing led by new investor Longitude Capital.

More From CBS Detroit

Best Christmas Light Displays
Best Holiday Drink Ideas
Top Hidden Destinations

Watch & Listen